Background and aims. The objectives of type 2 diabetes treatment are to achieve adequate long-term glycemic control and to reduce the risk associated with comorbidities and complications. Once-weekly Dulaglutide showed a reduction in cardiovascular risk associated with diabetes in addition to improved glycemic control and bodyweight reduction in several clinical trials. We aimed to investigate the effect of Dulaglutide 1.5 mg on glycemic and weight control in type 2 diabetes patients inadequately controlled by antihyperglycemic treatment in real-world clinical practice.

Methods. We retrospectively reviewed the medical records of 50 patients with type 2 diabetes inadequately controlled by previous  treatment and newly initiated on Dulaglutide. The data were collected at 6 months (n=50) and 12 months (n=40) after Dulaglutide therapy initiation.

Results. Dulaglutide treatment resulted in significant improvement of glycated hemoglobin (−1.3 %; p<0.001) after 6 months and after 12 months (−2.0 %; p<0.001). Significant bodyweight reduction was found after 6 months (−2.0 kg; p=0.002) and 12 months (−3.5 kg; p=0.001) of Dulaglutide treatment initiation. In addition, a reduction in insulin dose was observed.

Conclusions. Our  clinical data showed that Dulaglutide 1.5 mg significantly improved glycemic and bodyweight control at 6 and 12 months after treatment initiation in patients with type 2 diabetes inadequately controlled by previous  antihyperglycemic treatment.


diabetes mellitus, dulaglutide, bodyweight, glycemic control